Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel

Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.

More from US FDA Performance Tracker

More from Regulatory Trackers